SSTR陽性腫瘍を有する小児参加者におけるルテチウムLu 177エドトレオチド療法の用量を決定しPKを評価する第I相試験 (KinLET)
ソマトスタチン治療のための単独療法または標準治療 (SoC) としてのルテチウム Lu 177 エドトレオチド標的放射性医薬品療法 (RPT) の用量を決定し、薬物動態 (PK) と安全性を評価するための多施設共同非盲検介入第 I 相試験小児集団における受容体陽性腫瘍 (KinLET)。
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.
調査の概要
状態
詳細な説明
Determine the dose, pharmacokinetics and safety of Lutetium Lu 177 Edotreotide as monotherapy or following sequential standard of care in pediatric participants with recurrent, progressive or refractory NET, CNS, lymphoma and other solid tumors that express SSTRs by immunohistochemistry and demonstrate uptake by somatostatin receptor imaging. Lutetium Lu 177 Edotreotide will be given intravenously once every 8 weeks for a total of up to 6 doses over an average of 48 weeks in participants aged 2-18 years.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Serhii Melnyk, MD
- メール:kinlet@itm-radiopharma.com
研究連絡先のバックアップ
- 名前:Pia Zehkorn
- 電話番号:+4989 32989866000
- メール:kinlet@itm-radiopharma.com
研究場所
-
-
California
-
Palo Alto、California、アメリカ、94304
- 募集
- Lucile Packard Children's Hospital at Stanford
-
コンタクト:
- Raya Hamad Saab, Prof
- 電話番号:(650) 497-8953
- メール:rsaab@stanford.edu
-
San Francisco、California、アメリカ、94158
- 募集
- UCSF Benioff Children's Hospital
-
コンタクト:
- Kieuhoa T. Vo, MD
- 電話番号:415-476-3831
- メール:kieuhoa.vo@ucsf.edu
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- 募集
- Cincinnati Children's Hospital Medical Center
-
コンタクト:
- Brian K. Turpin, Do
- メール:brian.turpin@cchmc.org
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104-4319
- 募集
- The Children's Hospital of Philadelphia (CHOP)
-
コンタクト:
- Theodore W. Laetsch, MD
- メール:laetscht@chop.edu
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- University of Texas - MD Anderson Cancer Center
-
コンタクト:
- David McCall, MD
- メール:dmccall1@mdanderson.org
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitario Vall d'Hebron - Oncología Médica
-
コンタクト:
- Lucas Moreno, Dr.
- メール:lucas.moreno@vallhebron.cat
-
Madrid、スペイン、28009
- 募集
- Hospital General Universitario Gregorio Marañón
-
コンタクト:
- Cristina Mata Fernandez, Dr
- 電話番号:+34 915290037
- メール:cristina.mata@salud.madrid.org
-
-
-
-
-
Marseille、フランス、13005
- 募集
- CHU de Marseille - Hôpital de la Timone
-
コンタクト:
- Nicolas Andre, Prof
- メール:nicolas.andre@ap-hm.fr
-
Villejuif、フランス、94800
- 募集
- Gustave Roussy Cancer Campus
-
コンタクト:
- Charlotte Rigaud, Dr
- メール:charlotte.rigaud@gustaveroussy.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Participants aged ≥ 2 years and < 18 years
- Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease.
- Tumor which is relapsed or is refractory to at least one line of previous therapy
- Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample
- Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)/ computed tomography (CT) or positron emission tomography (PET)/CT imaging, which is higher than the liver uptake)
- Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial
- In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT
Screening Consent Participant/legal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
Key Exclusion Criteria:
- Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or excipients
- Previous history of acute leukemia unless in remission for at least two years
- Extensive bone/bone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells/kg
- Patients who have received previous systemic targeted RPT
- Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney.
- Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney.
- Previous treatment with oncologic immune vaccine or CAR-T cell therapy
- Bulky disease in the CNS
- Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction
- Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment
- Pregnant or breastfeeding women.
- Other known malignancies.
- Serious non-malignant disease.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Three sequential age cohorts
Arms are based upon age at enrollment. The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1, in the previous cohort.
|
lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
他の名前:
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pediatric Dosage
時間枠:a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
Pediatric dosage based on:
|
a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate
時間枠:At the end of Cycle 2 (each cycle is 28 days)
|
Assess preliminary anti-tumor activity by tumor type |
At the end of Cycle 2 (each cycle is 28 days)
|
|
PK and dosimetry
時間枠:Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
Lutetium Lu 177 edotreotide PK evaluation and tumor and target organ dosimetry |
Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
|
Rate of adverse events
時間枠:From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
Safety evaluation of Lutetium Lu 177 edotreotide targeted RPT as monotherapy or following standard of care |
From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
|
Overall Survival, Progression-Free Survival and Duration of Response
時間枠:Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
Additional preliminary efficacy evaluation of lutetium Lu 177 Edotreotide targeted RPT as monotherapy or following SoC |
Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Exploratory Endpoint: Quality of Life
時間枠:At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
Assess quality of life based on the adapted Quality of Life (QoL) scale (PedsQL TM 3.0 Cancer Module) |
At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
|
Exploratory Endpoint: Correlation between SSTR expression detected by immunohisto-chemistry and functional imaging
時間枠:No timeframe given.
|
Correlation of the expression level of SSTR immunohistochemistry in tumor biopsy or surgery samples and 111In-based, 99mTc-based, or 68Ga-based-based lesion uptake (regarding intensity/distribution) |
No timeframe given.
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Roman Henkel, PhD、Director, Global Clinical Operations
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ITM-1191-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。